Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;37(6):1757-1771.
doi: 10.1007/s11011-021-00844-y. Epub 2021 Oct 27.

Metabolism in Huntington's disease: a major contributor to pathology

Affiliations
Review

Metabolism in Huntington's disease: a major contributor to pathology

Akanksha Singh et al. Metab Brain Dis. 2022 Aug.

Abstract

Huntington's disease (HD) is a progressively debilitating neurodegenerative disease exhibiting autosomal-dominant inheritance. It is caused by an unstable expansion in the CAG repeat tract of HD gene, which transforms the disease-specific Huntingtin protein (HTT) to a mutant form (mHTT). The profound neuronal death in cortico-striatal circuits led to its identification and characterisation as a neurodegenerative disease. However, equally disturbing are the concomitant whole-body manifestations affecting nearly every organ of the diseased individuals, at varying extents. Altered central and peripheral metabolism of energy, proteins, nucleic acids, lipids and carbohydrates encompass the gross pathology of the disease. Intense fluctuation of body weight, glucose homeostasis and organ-specific subcellular abnormalities are being increasingly recognised in HD. Many of these metabolic abnormalities exist years before the neuropathological manifestations such as chorea, cognitive decline and behavioural abnormalities develop, and prove to be reliable predictors of the disease progression. In this review, we provide a consolidated overview of the central and peripheral metabolic abnormalities associated with HD, as evidenced from clinical and experimental studies. Additionally, we have discussed the potential of metabolic biomolecules to translate into efficient biomarkers for the disease onset as well as progression. Finally, we provide a brief outlook on the efficacy of existing therapies targeting metabolic remediation. While it is clear that components of altered metabolic pathways can mark many aspects of the disease, it is only conceivable that combinatorial therapies aiming for neuronal protection in consort with metabolic upliftment will prove to be more efficient than the existing symptomatic treatment options.

Keywords: Biomarker potential; Huntington’s disease; Metabolic dysfunction; Neurodegeneration; Peripheral tissues; Therapeutics.

PubMed Disclaimer

References

    1. Aditi K, Shakarad MN, Agrawal N (2016) Altered lipid metabolism in Drosophila model of Huntington’s disease. Sci Rep 6:31411. https://doi.org/10.1038/srep31411 - DOI - PubMed - PMC
    1. Aldaz T, Nigro P, Sánchez-Gómez A et al (2019) Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease. J Neurol 266:1340–1350. https://doi.org/10.1007/s00415-019-09263-7 - DOI - PubMed
    1. Andersen JV, Skotte NH, Aldana BI et al (2019) Enhanced cerebral branched-chain amino acid metabolism in R6/2 mouse model of Huntington’s disease. Cell Mol Life Sci 76:2449–2461. https://doi.org/10.1007/s00018-019-03051-2 - DOI - PubMed
    1. Andreassen OA, Dedeoglu A, Stanojevic V et al (2002) Huntington’s disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 11:410–424. https://doi.org/10.1006/nbdi.2002.0562 - DOI - PubMed
    1. Andrich J, Schmitz T, Saft C et al (2002) Autonomic nervous system function in Huntington’s disease. J Neurol Neurosurg Psychiatry 72:726–731. https://doi.org/10.1136/jnnp.72.6.726 - DOI - PubMed - PMC

Substances

LinkOut - more resources